News

Lundbeck reports better results with more to come

Wednesday 8 February 2017
Country
Denmark

H. Lundbeck A/S reported greatly improved results for 2016 as a result of a rolling restructuring that was initiated in the second half of 2015, leading the Danish neurology company to predict that it will improve profitability in the coming years to equal 25% of revenue before charges for interest and taxes. 

Prexton raises €29 million in Series B round

Tuesday 7 February 2017
Country
Switzerland

Prexton Therapeutics SA of Geneva, Switzerland has raised €29 million in a Series B financing round to support two Phase 2 studies of Foliglurax, an experimental compound for Parkinson’s disease that targets a positive allosteric modulator.

Genmab updates guidance for 2016

Monday 6 February 2017
Country
Denmark

Genmab A/S has upgraded its guidance for revenue and operating income in 2016 in light of higher than expected royalties on sales of Darzalex (daratumumab), a treatment for multiple myeloma, as well as milestone payments from its licensee Janssen Biotech Inc.

Novo Nordisk sees more price pressure

Friday 3 February 2017
Country
Denmark

Novo Nordisk A/S has made further adjustments to its financial forecast amidst downward pressure on insulin prices in the US and a decline in market share for its glucagon-like peptide-1 (GLP-1) medicine Victoza.

Biotec Pharmacon exploits the Arctic for medicines

Thursday 2 February 2017
Country
Norway

Biotec Pharmacon ASA, which uses Artic Ocean marine and plant life to develop sophisticated medicinal treatments and analytics, reported increases in revenue for the 2016 fourth quarter and full-year but also saw a widening of its loss.

AZ poised for growth

Thursday 2 February 2017
Country
United Kingdom

AstraZeneca Plc says that 2017 should be a turning point for the company as the loss of revenue from legacy products is overtaken by new drug launches, and core research and development spending levels out.

Roche expects sales growth in 2017

Wednesday 1 February 2017
Country
Switzerland

The Roche group was able to grow net income faster than sales in 2016 on the back of a series of new pharmaceutical product launches that included Tecentriq (atezolizumab), its first cancer immunotherapy. Tecentriq is a PD-L1 inhibitor for both bladder and lung cancer.

Insulin producers accused of price manipulation

Wednesday 1 February 2017
Country
United States

The US law firm, Hagens Berman Sobol Shapiro LLP, has filed a class action suit against Sanofi SA, Novo Nordisk A/S and Eli Lilly and Company alleging that they have used increasingly wider discounts from the list price of their analogue insulins to gain favour with pharmacy benefit managers and health insurers and thereby gained market share.

Novo Nordisk turns to Oxford for research

Wednesday 1 February 2017
Country
Denmark

Novo Nordisk A/S has turned to the University of Oxford for support in developing new approaches to treat Type 2 diabetes, a disease that affects nearly 9% of the global population. While Novo has a dominant global market position in the field, it is seeking to discover new treatments for people living with the disease and its complications.